Natural Product-Drug Interactions: Complex Mechanisms and Public Health Impact
Saturday April 06, 2019
2:00 pm
-
4:00 pm
Eastern Time (ET)
Room W206 A
CVP
DDD
DMDD
TOX
Chair :
Mary Paine
Washington State University
Amy Roe
Procter & Gamble Company
Global sales of botanical and other purported medicinal natural products (NPs) continue to rise, increasing the risk for adverse interactions with co-consumed conventional drugs, potentially leading to suboptimal therapeutic outcomes. Unlike for drug-drug interactions, rigorous guidelines for assessing NP-drug interactions are nonexistent. A multidisciplinary effort involving drug metabolism/pharmacokinetic scientists, clinical pharmacologists, NP chemists, and health informaticists is needed to develop rigorous guidelines for assessing and disseminating the drug interaction liability of NPs. Such guidelines should lead to improved design of future in vitro and clinical NP-drug interaction studies and ultimately, evidenced-based information regarding the optimal management of these complex interactions.
Speakers
Amy Roe
- Procter & Gamble Company
Botanical-Drug Interaction Assessment: A Critical Tier in a Systematic Approach to Botanical Safety
Chuan Li
- Shanghai Institution of Materia Medica, CAS
Chinese Herbal Medicines as Objects or Precipitants of Natural Product-Drug Interactions
Brandon Gufford
- Covance Inc.
Sharing is Caring: User-Centered Development of a Natural Product-Drug Interaction Information Portal
Dan-Dan Tian
- Washington State University
Differential Effects of Silymarin on Pitavastatin Disposition in Rodent Models of Simple Fatty Liver versus Nonalcoholic Steatohepatitis: a Natural Product-Disease-Drug Interaction
Bill Gurley
- University of Arkansas of Arkansas for Medical Sciences
'…Not Intended to Diagnose, Treat, Cure or Prevent Any Disease': 25 years of Botanical Dietary Supplement Usage and the Lessons Learned